- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ACCC Launches ICLIO for Community Oncologists
ICLIO promises to guide oncologists in community care practices to navigate the growing field of immuno-oncology.
Immuno-oncology, which has transformed the cancer treatment landscape, is rapidly being adopted into clinical practice and yielding promising results in oncology. However, questions about indications, biomarkers, cost of care, adverse effects, and reimbursement, remain. To help guide oncologists in community care practices to navigate this growing field, The Association of Community Cancer Centers has launched the Institute for Clinical Immuno-Oncology (ICLIO). Lee S. Schwartzberg, MD, FACP, chair of ICLIO had introduced ICLIO to our managed care readers through an article in Evidence-Based Oncology back in February.
ICLIO is open to all ACCC members, which includes more than 2000 cancer programs and 20,000 providers nationwide. ACCC estimates that nearly 60% of all cancer patients in the United States are treated by someone in the ACCC network.
Read the press release: http://prn.to/1dKhTgN
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
